Evidence map›Paper›PMID 31403034›Full record

ArticleFrontiers in oncology2019

Comprehensive Genomic Profiling of EBV-Positive Diffuse Large B-cell Lymphoma and the Expression and Clinicopathological Correlations of Some Related Genes.

Yangying Zhou, Zhijie Xu, Wei Lin, Yumei Duan, Can Lu, Wei Liu, Weiping Su, Yuanliang Yan, Huan Liu, Li Liu and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 55 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Yangying ZhouDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, China.
Zhijie XuDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, China.
Wei LinDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, China.
Yumei DuanDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, China.
Can LuDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, China.
Wei LiuDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, China.
Weiping SuDepartment of Orthopedics, Xiangya Hospital, Central South University, Changsha, China.
Yuanliang YanDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.
Huan LiuDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, China.
Li LiuDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, China.
Meizuo ZhongDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, China.
Jianhua ZhouDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, China.
Hong ZhuDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, China.
Xiangya Hospital Central South University · CNCentral South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (EBV+ DLBCL) is a rare type of lymphoma with a high incidence in elderly patients, poor drug response, and unfavorable prognosis. Despite advances in genomic profiling and precision medicine in DLBCL, EBV+ DLBCL remain poorly characterized and understood. We include 236 DLBCL patients for EBV-encoded mRNA (EBER)

Indexed as

EBV-positive diffuse large B-cell lymphoma (EBV+ DLBCL)fluorescence in situ hybridizationsimmunohistochemistryKMT2DMYCnext-generation sequencing

Identifiers

PMID31403034
PMCPMC6669985
OpenAlexW2959751431

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.